The phase III, multi-centered ADMIRAL trial comparing gilteritinib against salvage chemotherapy in patients with R/R AML and FLT3 mutations, revealed significantly longer OS (9.3 months vs. 5.6 months), with longer EFS and fewer grade three adverse events (AEs). The gene discussed is FLT3; the disease is acute myeloid leukemia.